Pipeline

Pipeline

Pipeline

Targeting Adaptive Stress

We have developed a differentiated pipeline of therapy candidates that address dynamic drivers of treatment resistance, cancer relapse and metastasis. We are actively developing our therapeutic candidates in clinical trials for large indications of unmet need for patients.

Our Pipeline


Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Adaptive Stress Modulators
Target Click HC-7366
(GCN2)
RCC
(monoTx)
HC-7366 monoTx
RCC
(HIF-2α inhibitor combo)
HC-7366 + HIF-2α
RCC
(VEGFR TKI combo)
HC-7366 + VEGFR TKI
RCC
(Immune checkpoint inhibitor combo)
HC-7366 + ICI
AML
(monoTx)
HC-7366 monoTx
AML
(SOC agents combo)
HC-7366 + SOC agents

HC-7366, is a differentiated selective, orally bioavailable modulator of a key stress response protein kinase, GCN2.  HC-7366 is under investigation in a Phase 1b trial as monotherapy and in combination with a HIF-2α inhibitor for the treatment of clear cell renal cell carcinoma.  HC-7366 is also under investigation in a Phase 1b study as monotherapy and in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML).

HC-5404
(PERK)
Target Click HC-5404
(PERK)
RCC
(VEGFR TKI combo)
HC-5404 + VEGFR TKI

HC-5404, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK.  HC-5404 recently completed investigation in a Phase 1a trial as a monotherapy for the treatment of advanced solid tumors enriched for patients with renal cell carcinoma (RCC) and gastric cancer.  Following the completion of our Phase 1a trial, a Phase 1b trial in combination with a VEGFR TKI is planned.



Targeting critical adaptive stress mitigating pathways

Modulating the immune system’s defense mechanisms